SCHEMBL8327503

SCHEMBL8327503

CCC(=O)N1CCCN(c2ccc(OC)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.61
▸ GFER P55789 3/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ MAPT P10636 5/20 0.60
▸ ALDH1A1 P00352 3/20 0.58
▸ LMNA P02545 2/20 0.58
▸ AKR1C3 P42330 1/20 0.57
▸ DRD3 P35462 1/20 0.56
▸ GAA P10253 1/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ HSD17B10 Q99714 2/20 0.55
▸ HPGD P15428 1/20 0.55
▸ TSHR P16473 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12182367 0.94 L3MBTL1 (0.68) L3MBTL1GFERMAPK1MAPTALDH1A1
SCHEMBL8327088 0.89 MAPT (0.62) L3MBTL1GFERMAPK1MAPTALDH1A1
SCHEMBL8325536 0.83 MAPT (0.68) L3MBTL1GFERMAPK1MAPTALDH1A1
SCHEMBL19002658 0.82 MAPT (0.57) L3MBTL1GFERMAPK1MAPTALDH1A1
SCHEMBL945994 0.81 L3MBTL1 (0.66) L3MBTL1GFERMAPK1MAPTALDH1A1
SCHEMBL17260630 0.81 MAPT (0.67) L3MBTL1GFERMAPK1MAPTALDH1A1
SCHEMBL30862676 0.80 DRD3 (0.59) GFERMAPK1MAPTALDH1A1LMNA
SCHEMBL2766451 0.79 POLB (0.67) L3MBTL1GFERMAPK1MAPTALDH1A1
SCHEMBL9987782 0.79 MAPT (0.67) L3MBTL1GFERMAPK1MAPTALDH1A1
SCHEMBL14224740 0.79 LMNA (0.63) MAPK1MAPTALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592426-B1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2007-12-19 — — EP disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 — — WO disclosed
Send feedback